Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 125,740,504
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.61
  • Price/Sales 7.87
  • Price/Cash Flow 21.14
  • Price/Book 17.56

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.35 +4.14%
on 10/13/17
49.85 -1.08%
on 10/16/17
+1.12 (+2.32%)
since 09/15/17
3-Month
41.03 +20.18%
on 07/27/17
49.85 -1.08%
on 10/16/17
+6.22 (+14.43%)
since 07/17/17
52-Week
30.89 +59.63%
on 11/23/16
49.85 -1.08%
on 10/16/17
+8.98 (+22.27%)
since 10/17/16

Most Recent Stories

More News
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

LGND : 142.15 (+0.29%)
CELG : 138.86 (+1.57%)
NVO : 49.31 (-0.02%)
VRTX : 155.05 (+0.23%)
NVS : 86.34 (-0.03%)
GILD : 80.24 (+0.36%)
PFE : 36.20 (+0.61%)
Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

NVO : 49.31 (-0.02%)
ABBV : 92.17 (+1.24%)
REGN : 442.56 (-0.70%)
SNY : 49.59 (-0.08%)
Immune Design's Sarcoma Candidate to Enter Phase III in 2018

Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.

CELG : 138.86 (+1.57%)
NVO : 49.31 (-0.02%)
IMDZ : 8.20 (-18.81%)
ADAP : 7.01 (-4.37%)
Bristol-Myers Gets Priority Review for Opdivo Label Expansion

Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

AZN : 34.78 (+0.38%)
NVO : 49.31 (-0.02%)
MRK : 63.22 (-0.19%)
BMY : 64.18 (+0.83%)
Technical Snapshots for These Drug Makers Stocks -- SciClone Pharma, Synergy Pharma, Novo Nordisk, and United Therapeutics

If you want a Stock Review on SCLN, SGYP, NVO, or UTHR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today's investors' attention is directed to...

SCLN : 11.15 (unch)
NVO : 49.31 (-0.02%)
SGYP : 3.03 (-0.33%)
UTHR : 121.79 (+1.68%)
Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

CELG : 138.86 (+1.57%)
NVO : 49.31 (-0.02%)
ADAP : 7.01 (-4.37%)
GSK : 40.83 (-0.07%)
Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide

Bagsvaerd, Denmark, 16 October 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss...

NVO : 49.31 (-0.02%)
Why Should You Invest in Novo Nordisk (NVO) Stock Right Now

Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.

BAYRY : 35.0600 (-0.65%)
NVO : 49.31 (-0.02%)
ACAD : 36.99 (+2.47%)
ADRO : 9.65 (+1.58%)
Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal

The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.

MYL : 38.54 (+0.94%)
NVO : 49.31 (-0.02%)
LLY : 86.06 (+0.13%)
AGN : 197.78 (-0.32%)
TEVA : 14.74 (+0.20%)
GSK : 40.83 (-0.07%)
SNY : 49.59 (-0.08%)
4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3

The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.

BAYRY : 35.0600 (-0.65%)
NVO : 49.31 (-0.02%)
JNJ : 140.79 (+3.43%)
MRK : 63.22 (-0.19%)
LLY : 86.06 (+0.13%)
NVS : 86.34 (-0.03%)
PFE : 36.20 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 49.99
1st Resistance Point 49.65
Last Price 49.31
1st Support Level 48.88
2nd Support Level 48.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart